Back to School: How biopharma can reboot drug development. Access exclusive analysis here
When attorneys for Amgen Inc. and Transkaryotic Therapies Inc. appear in trial court May 15, the bottom line, at least initially, will be whether TKTX can show that claim one
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury